Advertisement

Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study

      Highlights

      • HCV clearance by direct-acting antivirals (DAA) significantly reduces the annual incidence of cardio vascular events by 0.68%.
      • Incident cardiovascular events (CV) rates for 100 patient years in controls was 1.14 and in cases 0.44.
      • The CV risk after HCV clearance was reduced by 2.0–3.5 folds.
      • The calculated number of patients to be treated to get a benefit in a patient was 55.26.
      • HCV clearance was independently associated with CV events reduction.

      Abstract

      Background and aims

      HCV is associated with an increased risk of cardiovascular events (CV). Whether HCV clearance by direct-acting antivirals (DAA) reduces incident CV disease is poorly understood. We investigate whether HCV eradication reduces CV events.

      Methods

      In a prospective multicentre study, 2204 HCV patients (F0–F2:29.5%, F3–F4: 70.5%) were enrolled. Males were 48%, median age was 68 (59–74) years and BMI 25.9 (23.1–28); 24.7% were smokers, 18% had diabetes, 13.2% had cholesterol levels >200 mg/dl and 9.1% took statins, 44% had hypertension. During an overall median follow-up of 28 (24–39) months, incident CV events, such as ischemic heart disease (IHD) and ischemic cerebral stroke (ICS), were recorded. An overall of 2204 patients were evaluated as control group and 1668 patients after HCV elimination were followed as a case group. Factors associated with CV events were evaluated by uni- and multi-variate analyses.

      Results

      Incident CV rates per 100 patient years in pre-treatment and untreated controls and treated cases were 1.12, 1.14 and 0.44 (p = 0.0001 vs. controls), respectively, and a decreased of relative risk (RR = 0.379; p = 0.0002) was observed. CV risk was 2.0–3.5 times lower then in controls (HR 3.671; 95%C.I.:1.871–7.201; p < 0.001). The calculated number of patients to be treated to get a benefit in a patient was 55.26. The annual incidence reduction of CV events was 0.68%. HCV clearance was independently associated with CV events reduction (OR, 4.716; 95% C.I.:1.832–12.138; p = 0.001).

      Conclusions

      HCV clearance by DAA reduces CV events (IHD and ICS) with both clinical and socio-economic benefits.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Younossi Z.M.
        Hepatitis C infection: a systemic disease.
        Clin. Liver Dis. 2017; 21: 449-453
        • Adinolfi L.E.
        • Restivo L.
        • Zampino R.
        • et al.
        Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis.
        Atherosclerosis. 2012; 221: 496-502
        • Petta S.
        • Torres D.
        • Fazio G.
        • et al.
        Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations.
        Hepatology. 2012; 55: 1317-1323
        • Butt A.A.
        • Yan P.
        • Chew K.W.
        • et al.
        Risk of acute myocardial infarction among hepatitis C virus (HCV)-Positive and HCV-negative men at various lipid levels: results from ERCHIVES.
        Clin. Infect. Dis. 2017; 65: 557-565
        • Pothineni N.V.
        • Delongchamp R.
        • Vallurupalli S.
        • et al.
        Impact of hepatitis C seropositivity on the risk of coronary heart disease events.
        Am. J. Cardiol. 2014; 114: 1841-1845
        • Maruyama S.
        • Koda M.
        • Oyake N.
        • et al.
        Myocardial injury in patients with chronic hepatitis C infection.
        J. Hepatol. 2013; 58: 11-15
        • Wu V.C.
        • Chen T.H.
        • Wu M.
        • et al.
        Risk of cardiac arrhythmias in patients with chronic hepatitis B and C infections - a 13-year nationwide population-based study.
        J. Cardiol. 2019 Apr 11; (pii: S0914-5087): 30081-30084
        • Huang H.
        • Kang R.
        • Zhao Z.
        Is hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis.
        PloS One. 2014; 9e106376
        • Petta S.
        • Maida M.
        • Macaluso F.S.
        • et al.
        Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies.
        Gastroenterology. 2016; 150: 145-155
        • Adinolfi L.E.
        • Restivo L.
        • Guerrera B.
        • et al.
        Chronic HCV infection is a risk factor of ischemic stroke.
        Atherosclerosis. 2013; 231: 22-26
        • Liao C.C.
        • Su T.C.
        • Sung F.C.
        • Chou W.H.
        • Chen T.L.
        Does hepatitis C virus infection increase risk for stroke? A population-based cohort study.
        PloS One. 2012; 7e31527
        • Huang He
        • Kang R.
        • Zhao Z.
        Hepatitis C virus infection and risk of stroke: a systematic review and meta-analysis.
        PloS One. 2013; 8e81305
        • Ambrosino P.
        • Lupoli R.
        • Di Minno A.
        • et al.
        The risk of coronary artery disease and cerebrovascular disease in patients with hepatitis C: a systematic review and meta-analysis.
        Int. J. Cardiol. 2016; 221: 746-754
        • Lee M.H.
        • Yang H.I.
        • Lu S.N.
        • et al.
        • R.E.V.E.A.L. HCV Study Group
        Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study.
        J. Infect. Dis. 2012; 206: 469-477
        • Guiltinan A.M.
        • Kaidarova Z.
        • Custer B.
        • et al.
        Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors.
        Am. J. Epidemiol. 2008; 167: 743-750
        • El-Kamary S.S.
        • Jhaveri R.
        • Shardell M.D.
        All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population.
        Clin. Infect. Dis. 2011; 53: 150-157
        • Berenguer J.
        • Rodríguez E.
        • Miralles P.
        • et al.
        GESIDA HIV/HCV Cohort Study Group. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.
        Clin. Infect. Dis. 2012; 55: 728-736
        • Mahale P.
        • Engels E.A.
        • Li R.
        • et al.
        The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
        Gut. 2018; 67: 553-561
        • Petta S.
        • Adinolfi L.E.
        • Fracanzani A.L.
        • et al.
        Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
        J. Hepatol. 2018; 69: 18-24
        • Adinolfi L.E.
        • Nevola R.
        • Guerrera B.
        • et al.
        Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients.
        J. Gastroenterol. Hepatol. 2018; 33: 1379-1382
        • Butt A.A.
        • Yang P.
        • Shuaib A.
        • Abu-Samra A.-B.
        • Shaikh O.S.
        • Freiberg M.S.
        Direct-acting antiviral therapy for HCV infection is associated with a reduced risk of cardiovascular disease events.
        Gastroenterology. 2019; 156: 978-996
        • Luepker R.V.
        • Apple F.S.
        • Christenson R.H.
        • et al.
        Circulation. 2003; 108: 2543-2549
        • Sacco R.L.
        • Kasner S.E.
        • Broderick J.P.
        • et al.
        An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association.
        Stroke. 2013; 44: 2064-2089
        • American Diabetes Association
        Classification and diagnosis of diabetes: standards of medical care in diabetes-2018.
        Diabetes Care. 2018; 41: S13-S27
        • European Association for the Study of the Liver
        EASL recommendations on treatment of hepatitis C 2018.
        J. Hepatol. 2018; 69: 461-511
        • Lee K.K.
        • Stelzle D.
        • Bing R.
        • et al.
        Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study.
        Lancet Gastroenterol Hepatol. 2019; 4: 794-804
        • Petta S.
        Hepatitis C virus and cardiovascular: a review.
        J. Adv. Res. 2017; 8: 161-168
        • Mehta D.A.
        • Cohen E.
        • Charafeddine M.
        • et al.
        Effect of hepatitis C treatment with ombitasvir/paritaprevir/r+ dasabuvir on renal, cardiovascular and metabolic extrahepatic manifestations: a post-hoc analysis of phase 3 clinical trials.
        Infect. Dis. Ther. 2017; 6: 515-529
        • Adinolfi L.E.
        • Rinaldi L.
        • Marrone A.
        • Giordano M.
        The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C.
        Expert Rev. Anti Infect. Ther. 2018; 16: 595-597
        • Mascia C.
        • Vita S.
        • Zuccalà P.
        • et al.
        Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon.
        PloS One. 2017; 12e0179400
        • Hsu C.S.
        • Kao J.H.
        • Chao Y.C.
        • et al.
        Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan.
        Aliment. Pharmacol. Ther. 2013; 38: 415-423
        • Hsu Y.C.
        • Lin J.T.
        • Ho H.J.
        • et al.
        Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.
        Hepatology. 2014; 59: 1293-1302
        • Gragnani L.
        • Visentini M.
        • Fognani E.
        • et al.
        Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.
        Hepatology. 2016; 64: 1473-1482
        • Tardif J.C.
        • Kouz S.
        • Waters D.D.
        • et al.
        Efficacy and safety of low-dose colchicine after myocardial infarction.
        N. Engl. J. Med. 2019; 381: 2497-2505
        • Ridker P.M.
        • MacFadyen J.G.
        • Thuren T.
        • Libby P.
        • on behalf of the CANTOS Trial Group
        Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.
        Eur. Heart J. 2019; Sep 1; (pii: ehz542. [Epub ahead of print])https://doi.org/10.1093/eurheartj/ehz542
        • Fountoulaki K.
        • Tsiodras S.
        • Polyzogopoulou E.
        • et al.
        Beneficial effects of vaccination on cardiovascular events: myocardial infarction, stroke, heart failure.
        Cardiology. 2018; 141: 98-106

      Linked Article